Brethine
(Terbutaline)ApprovedSmall molecule
SanofiTerbutaline is used to treat asthma and chronic obstructive pulmonary disease (COPD) by relaxing the muscles in the airways to help you breathe easier. It can be used both to prevent symptoms and to treat sudden breathing problems.[2] Brethine is currently approved and in use across 10 indications[4].[1]
Brethine is one of 208 small molecule programs targeting Airway obstruction. It is currently in Approved.
10
Indications
23
Total Trials
2
Active Trials
207
Competitors
6
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Indication
Competition
Competitive Landscape
206 competitors in Heart Failure
#DrugCompanyPhaseTrials
1Brethine
SanofiApproved
Bayer Aspirin
BayerPreclinical
Medrol
PfizerPreclinical
Amidate
PfizerPreclinical
Activase
RochePreclinical
Zemplar
AbbViePreclinical
Adriamycin
PfizerPreclinical
Savaysa
Daiichi SankyoPreclinical
Xifaxan
SSalix
Preclinical
Xylocaine
MMEDRx USA, Inc.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Asthma4 trials
Immune Thrombocytopenia2 trials
13 more indications
Hypoglycemia1 trial
Type 1 Diabetes1 trial
Side Effects1 trial
Status Asthmaticus1 trial
Trial of Terbutaline for the Treatment of Status Asthmaticus in Children
Completed·—·Phase 4·NCT00124995·40 enrolled
Renal Colic1 trial
Unspecified1 trial
Regulatory
FDA Approval Timeline[5]
Jan 1, 1982
BRETHINE
NDA NDA018571
Jan 1, 1982
BRICANYL
NDA NDA017466
Jan 1, 1982
BRETHINE
NDA NDA017849
Jan 1, 1982
BRICANYL
NDA NDA017618
Aug 17, 1984
BRETHAIRE
NDA NDA018762
Mar 19, 1985
BRICANYL
NDA NDA018000
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Brethine drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Terbutaline. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]